Last reviewed · How we verify
P-3073
P-3073 is a small molecule inhibitor of the PI3K delta subunit.
P-3073 is a small molecule inhibitor of the PI3K delta subunit. Used for Relapsing multiple sclerosis.
At a glance
| Generic name | P-3073 |
|---|---|
| Sponsor | Polichem S.A. |
| Drug class | PI3K delta inhibitor |
| Target | PI3K delta |
| Modality | Small molecule |
| Therapeutic area | Immunology |
| Phase | Phase 3 |
Mechanism of action
P-3073 works by selectively inhibiting the PI3K delta subunit, which is involved in the activation of immune cells. This inhibition leads to a reduction in the activity of these cells, resulting in anti-inflammatory effects. By targeting the PI3K delta subunit, P-3073 has the potential to treat various inflammatory and autoimmune diseases.
Approved indications
- Relapsing multiple sclerosis
Common side effects
- Nausea
- Diarrhea
- Headache
Key clinical trials
- Study to Evaluate the Efficacy and Safety of P-3073 Nail Solution in the Treatment of Nails Affected by Psoriasis (PHASE3)
- Study to Evaluate the Efficacy and Safety of P-3073 Nail Solution in the Treatment of Mild to Moderate Psoriatic Fingernail/s (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- P-3073 CI brief — competitive landscape report
- P-3073 updates RSS · CI watch RSS
- Polichem S.A. portfolio CI